In vivo imaging assay for the convenient evaluation of antiviral compounds against cytomegalovirus in mice

Antiviral Research

Volumn 88, Issue 1, 2010, Pages 45-52

  Yamada, Souichi ^a   Kosugi, Isao ^b   Katano, Harutaka ^a   Fukui, Yoshiko ^a   Kawasaki, Hideya ^b   Arai, Yoshifumi ^b   Kurane, Ichiro ^a   Inoue, Naoki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1 (3,5 dichloro 4 pyridyl)piperidine 4 carboxamide (DPPC); DsRed2; EGFP; Fluorescence; Ganciclovir; Hairless; In vivo imaging; Mouse; Murine cytomegalovirus (MCMV)

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GANCICLOVIR; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; HAIRLESS MOUSE; HISTOPATHOLOGY; IMAGING; IN VIVO IMAGING; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS;

ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FLUORESCENCE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GANCICLOVIR; GREEN FLUORESCENT PROTEINS; HERPESVIRIDAE INFECTIONS; MICE; MICE, HAIRLESS; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUROMEGALOVIRUS; POLYMERASE CHAIN REACTION;

ANIMALIA; CYTOMEGALOVIRUS; MAIZE CHLOROTIC MOTTLE VIRUS; MURID HERPESVIRUS 1; MURINAE; MUS;

EID: 77956913684     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.07.002     Document Type: Article

References (34)

1. Alexander R., Lamb D., White D., Wentzel T., Politis S., Rijnsburger J., van Ruyven D., Kelly N., Garland S.M. 'RETCIF': a rapid, sensitive method for detection of viruses, applicable for large numbers of clinical samples. J. Virol. Meth. 2001, 97:77-85.
2. Allan J.E., Shellam G.R. Genetic control of murine cytomegalovirus infection: virus titres in resistant and susceptible strains of mice. Arch. Virol. 1984, 81:139-150.
3. Arai Y., Ishiwata M., Baba S., Kawasaki H., Kosugi I., Li R.Y., Tsuchida T., Miura K., Tsutsui Y. Neuron-specific activation of murine cytomegalovirus early gene e1 promoter in transgenic mice. Am. J. Pathol. 2003, 163:643-652.
4. Bedard J., May S., Barbeau D., Yuen L., Rando R.F., Bowlin T.L. A high throughput colorimetric cell proliferation assay for the identification of human cytomegalovirus inhibitors. Antiviral Res. 1999, 41:35-43.
5. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006, 71:154-163.
6. Braitman A., Swerdel M.R., Olsen S.J., Tuomari A.V., Lynch J.S., Blue B., Michalik T., Field A.K., Bonner D.P., Clark J.M. Evaluation of SQ 34,514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice. Antimicrob. Agents Chemother. 1991, 35:1464-1468.
7. Bravo F.J., Cardin R.D., Bernstein D.I. A model of human cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 2007, 76:104-110.
8. Dal Pozzo F., Andrei G., Daelemans D., Winkler M., Piette J., De Clercq E., Snoeck R. Fluorescence-based antiviral assay for the evaluation of compounds against vaccinia virus, varicella zoster virus and human cytomegalovirus. J. Virol. Meth. 2008, 151:66-73.
9. De Clercq E. New inhibitors of human cytomegalovirus (HCMV) on the horizon. J. Antimicrob. Chemother. 2003, 51:1079-1083.
10. Duan J., Paris W., Kibler P., Bousquet C., Liuzzi M., Cordingley M.G. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 1998, 39:189-197.
11. Fukui Y., Shindoh K., Yamamoto Y., Koyano S., Kosugi I., Yamaguchi T., Kurane I., Inoue N. Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay. Antimicrob. Agents Chemother. 2008, 52:2420-2427.
12. Gilbert C., Boivin G. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure. Antimicrob. Agents Chemother. 2005, 49:4860-4866.
13. Hsu K.M., Pratt J.R., Akers W.J., Achilefu S.I., Yokoyama W.M. Murine cytomegalovirus displays selective infection of cells within hours after systemic administration. J. Gen. Virol. 2009, 90:33-43.
14. Ishiwata M., Baba S., Kawashima M., Kosugi I., Kawasaki H., Kaneta M., Tsuchida T., Kozuma S., Tsutsui Y. Differential expression of the immediate-early 2 and 3 proteins in developing mouse brains infected with murine cytomegalovirus. Arch. Virol. 2006, 151:2181-2196.
15. Katano H., Sato Y., Tsutsui Y., Sata T., Maeda A., Nozawa N., Inoue N., Nomura Y., Kurata T. Pathogenesis of cytomegalovirus-associated labyrinthitis in a guinea pig model. Microbes Infect. 2007, 9:183-191.
16. Kern E.R. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antiviral Res. 2006, 71:164-171.
17. Kern E.R., Bidanset D.J., Hartline C.B., Yan Z., Zemlicka J., Quenelle D.C. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob. Agents Chemother. 2004, 48:4745-4753.
18. Kimberlin D.W., Lin C.Y., Sanchez P.J., Demmler G.J., Dankner W., Shelton M., Jacobs R.F., Vaudry W., Pass R.F., Kiell J.M., Soong S.J., Whitley R.J. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003, 143:16-25.
19. Luker G.D., Bardill J.P., Prior J.L., Pica C.M., Piwnica-Worms D., Leib D.A. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J. Virol. 2002, 76:12149-12161.
20. Luker K.E., Luker G.D. Applications of bioluminescence imaging to antiviral research and therapy: multiple luciferase enzymes and quantitation. Antiviral Res. 2008, 78:179-187.
21. Marschall M., Freitag M., Weiler S., Sorg G., Stamminger T. Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrob. Agents Chemother. 2000, 44:1588-1597.
22. McSharry J.J. Analysis of virus-infected cells by flow cytometry. Methods 2000, 21:249-257.
23. Oliver S.L., Zerboni L., Sommer M., Rajamani J., Arvin A.M. Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts. J. Virol. Methods 2008, 154:182-193.
24. Pass R.F. Cytomegalovirus. Fields Virology 2001, 2675-2705. Lippincott Williams & Wilkins, Philadelphia, PA. 4th ed. D.M. Knipe, P.M. Howley (Eds.).
25. Reefschlaeger J., Bender W., Hallenberger S., Weber O., Eckenberg P., Goldmann S., Haerter M., Buerger I., Trappe J., Herrington J.A., Haebich D., Ruebsamen-Waigmann H. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother. 2001, 48:757-767.
26. Sacher T., Podlech J., Mohr C.A., Jordan S., Ruzsics Z., Reddehase M.J., Koszinowski U.H. The major virus-producing cell type during murine cytomegalovirus infection, the hepatocyte, is not the source of virus dissemination in the host. Cell Host. Microbe 2008, 3:263-272.
27. Siennicka J., Trzcinska A., Kantoch M. Evaluation of antiviral activity of different origin compounds by flow cytometry. Acta Microbiol. Pol. 2002, 51:79-83.
28. Smith L.M., McWhorter A.R., Masters L.L., Shellam G.R., Redwood A.J. Laboratory strains of murine cytomegalovirus are genetically similar to but phenotypically distinct from wild strains of virus. J. Virol. 2008, 82:6689-6696.
29. Straus S.E., Aulakh H.S., Ruyechan W.T., Hay J., Casey T.A., Vande Woude G.F., Owens J., Smith H.A. Structure of varicella-zoster virus DNA. J. Virol. 1981, 40:516-525.
30. Tsutsui Y., Kashiwai A., Kawamura N., Aiba-Masago S., Kosugi I. Prolonged infection of mouse brain neurons with murine cytomegalovirus after pre- and perinatal infection. Arch. Virol. 1995, 140:1725-1736.
31. Visalli R.J., van Zeijl M. DNA encapsidation as a target for anti-herpesvirus drug therapy. Antiviral Res. 2003, 59:73-87.
32. Weber O., Bender W., Eckenberg P., Goldmann S., Haerter M., Hallenberger S., Henninger K., Reefschlager J., Trappe J., Witt-Laido A., Ruebsamen-Waigmann H. Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Res. 2001, 49:179-189.
33. Winston D.J., Young J.A., Pullarkat V., Papanicolaou G.A., Vij R., Vance E., Alangaden G.J., Chemaly R.F., Petersen F., Chao N., Klein J., Sprague K., Villano S.A., Boeckh M. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008, 111:5403-5410.
34. Zaitseva M., Kapnick S.M., Scott J., King L.R., Manischewitz J., Sirota L., Kodihalli S., Golding H. Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice. J. Virol. 2009, 83:10437-10447.